Shuttle Pharmaceuticals Files 8-K on Officer/Director Changes
Ticker: SHPH · Form: 8-K · Filed: Sep 17, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, officer-appointment, director-election, compensation
TL;DR
Shuttle Pharma 8-K: Director/Officer changes and compensation updates filed.
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. filed an 8-K on September 17, 2025, reporting events as of September 11, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are not provided in this excerpt.
Why It Matters
Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key personnel and compensation arrangements can introduce uncertainty regarding the company's future direction and stability.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- September 11, 2025 (date) — Date of earliest event reported
- September 17, 2025 (date) — Date of report
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific individuals and their roles are not detailed in this excerpt.
What is the nature of the compensatory arrangements mentioned?
The filing states that there are compensatory arrangements of certain officers, but the specifics of these arrangements are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 11, 2025.
What is the filing date of this 8-K report?
This 8-K report was filed on September 17, 2025.
What is the principal executive office address for Shuttle Pharmaceuticals Holdings, Inc.?
The principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
Filing Stats: 406 words · 2 min read · ~1 pages · Grade level 12.1 · Accepted 2025-09-17 16:26:19
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-25-013890.txt ( ) — 197KB
- shph-20250911.xsd (EX-101.SCH) — 3KB
- shph-20250911_lab.xml (EX-101.LAB) — 33KB
- shph-20250911_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: September 17, 2025 By: /s/ Christopher Cooper Name: Christopher Cooper Title: Interim Chief Executive Officer 3